生命科学资讯

Trump unveils healthcare affordability plan

The clinical candidates pharma execs are tracking

It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?

Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs

3 positive trends for Massachusetts’ biopharma sector

A biotech’s snakebite pill is drawing the US military’s interest

What Sanofi’s multiple sclerosis troubles could mean for the space

PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D

The wellness industry is HHS’ new belle of the ball

Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?

C-suite priorities give a sneak peek into AI’s pharma future

5 FDA drug approvals to watch in 2026

PharmaVoice’s Crystal Ball: Market and policy forces shaping the industry

3 of China’s most innovative pharma companies

Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D

Biopharma CEO optimism is wavering in the U.S.

Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth

The leading GLP-1 contenders in pharma’s race for an obesity pill

3 key takeaways from the FDA’s new animal testing guidance

How the FDA could soon upend vaccine trials